Developmental and Epileptic Encephalopathies: Emerging Approaches to Treatment

Saturday, December 4, 2021
-

You may need to log in to view video on this page.

OVERVIEW:

Developmental Epileptic Encephalopathies (DEEs) are devastating conditions marked by treatment-resistant seizures, abnormal electroencephalogram activity, and significant comorbid neurodevelopmental challenges. This symposium will highlight three DEEs focusing on phenotypic manifestations and approaches to the diagnosis and management of patients. These include tuberous sclerosis complex (TSC), PCDH19 epilepsy, and CDKL5 deficiency disorder (CDD). They are all rare, refractory epilepsies, with unique clinical presentations, neurodevelopmental comorbidities, significant treatment challenges, and considerable humanistic burden. The scientific landscape concerning these DEEs is rapidly advancing in all areas, including basic science, genetics, classification, diagnosis, and treatment.

Sponsor: Marinus Pharmaceuticals, Inc.

Learning Objectives:

Following participation in this activity, learners will be able to:

  • Discuss phenotypic manifestations of tuberous sclerosis complex and current and investigational treatment approaches 
  • Review clinical features of PCDH19 epilepsy and current and investigational treatment approaches 
  • Review clinical presentations in CDKL5 deficiency disorder and current and investigational treatment approaches

Education Credit:

CME provided by Miller Medical Communications, LLC

Activity Type
Satellite Symposia
Credit
CME
Format
In person
Career Stage
Early Career (typically 0-5 years from completion of training)
Mid-Career (typically 6-15 years from completion of training)
Senior (typically >15 years from completion of training)
Audience
Behavioral Health Providers
Clinicians
Fellows/Trainees
Nurses
Scientists/Researchers
Advanced Practice Providers
Advocates
Pharmacists
Technicians
Demographic
Clinical
First-time Attendees
Research
Young Professionals